18 results
8-K
EX-99.1
ZLAB
Zai Lab Limited
10 May 22
Zai Lab Announces First Quarter 2022
4:10pm
with niraparib compared to placebo: 24.8 months versus 8.3 months, hazard ratio (HR), 0.45; p<0.001. Other pre-specified efficacy results included … was 12.1 months, compared with 7.9 months for the matched-control patients in EF-14 (hazard ratio=0.46, p=0.033).
mOS was 25.2 months, compared with 15.9
8-K
EX-99.1
n3w7nah2g
31 Mar 21
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal
7:32am
10-K
avks7
1 Mar 21
Annual report
12:00am
10-K
EX-10.32
l0dlh
1 Mar 21
Annual report
12:00am
10-K
EX-10.33
c8rhv0hodwv mfx87w8
1 Mar 21
Annual report
12:00am
6-K
EX-99.1
l2wuh8xq3xzb2 reyhh
29 Dec 20
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
7:30am
6-K
EX-99.1
gv7qq
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
EX-99.1
runt qagatwy
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am
6-K
EX-99.1
q3fc2yw4sstwjduvp t9
20 Jul 20
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
7:35am
6-K
EX-99.1
672n23wr y4bk6l
27 Dec 19
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer
7:51am
6-K
EX-99.1
8kq qakcf31fnf4
22 Oct 18
Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong
7:48am
20-F
plf7mvapea5odetys3
30 Apr 18
Annual report (foreign)
9:07am
- Prev
- 1
- Next